Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Portfolio Pulse from Vandana Singh
Exelixis Inc, Roche Holdings AG, and Ipsen announced that their Phase 3 CONTACT-02 pivotal trial evaluating Cabometyx in combination with Tecentriq has met one of the primary endpoints, showing a significant improvement in progression-free survival. The trial is for patients with metastatic castration-resistant prostate cancer. The estimated total U.S. market value is approximately $1.9 billion. Analysts from William Blair maintain the Outperform rating on Exelixis' stock.
August 21, 2023 | 6:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis' combo therapy with Roche and Ipsen meets primary endpoint in Phase 3 trial, potentially opening up a $1.9B market. William Blair maintains Outperform rating.
The positive results from the Phase 3 trial could potentially open up a significant market for Exelixis, positively impacting its stock. The maintained Outperform rating by William Blair also indicates a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Ipsen's combo therapy with Exelixis and Roche meets primary endpoint in Phase 3 trial, potentially opening up a $1.9B market.
The positive results from the Phase 3 trial could potentially open up a significant market for Ipsen, positively impacting its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's combo therapy with Exelixis and Ipsen meets primary endpoint in Phase 3 trial, potentially opening up a $1.9B market.
The positive results from the Phase 3 trial could potentially open up a significant market for Roche, positively impacting its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80